Healthcare Investment in China Needs More Than Capital

The Capital Paradox

Shanghai hosted over 30 business leaders and investors last week during BioShanghai Week 2026, and the conversation circled back to a recurring frustration: healthcare ventures in Greater China are drowning in early-stage capital yet struggling to cross the valley between clinical promise and commercial viability. The roundtable, which brought together mainland China and Hong Kong investors, underscored a structural tension that has defined the sector for the past five years.

Nisa Leung, founding managing partner of Aulis Capital, and Dr Kenneth Tsang, regional chief executive officer of IHH Healthcare North Asia, anchored the discussion. Both operate at different points in the capital lifecycle, yet both see the same bottleneck. China's healthcare sector attracted USD 12.8 billion in venture funding in 2025, according to data from Zero2IPO Research, yet fewer than 15 per cent of Series A companies reached profitability within five years. That gap is not a failure of innovation. It is a failure of infrastructure.

Where the Model Breaks

The venture model imported from Silicon Valley assumes that capital can buy time, and time can buy product-market fit. In healthcare, that assumption collapses under the weight of regulatory approvals, provincial reimbursement negotiations, and hospital procurement cycles that can stretch beyond 18 months. A diagnostic device approved by the National Medical Products Administration in Beijing may wait two years before a Tier 2 hospital in Chengdu adds it to its formulary. By then, the startup has burned through its Series B.

Dr Tsang noted that IHH Healthcare North Asia, which operates hospitals across Hong Kong and mainland China, sees dozens of pitches each quarter from medtech and digital health startups. The pattern is familiar: strong clinical data, enthusiastic pilot partners, and no clear path to scale. The missing link is not technology. It is distribution, reimbursement strategy, and relationships with provincial health commissions. These are not problems venture capital solves well.

Aulis Capital has carved a niche by taking a hands-on approach that extends beyond writing cheques. Leung described a model in which the firm embeds advisers into portfolio companies to navigate regulatory submissions, build hospital relationships, and structure pricing models that align with China's tiered reimbursement system. This level of operational support is resource-intensive, and it narrows the funnel of investable opportunities. But it also raises success rates. Aulis-backed companies have a 60 per cent higher likelihood of reaching Series C compared to the sector average, according to internal data shared at the roundtable.

The Post-Listing Mirage

The Hong Kong Stock Exchange amended Chapter 18A in 2018 to allow pre-revenue biotech companies to list, and the Shanghai STAR Market followed with similar rules in 2019. The intention was to create liquidity for healthcare innovators. The reality has been more complicated. Between 2020 and 2025, 87 healthcare companies listed on HKEX under Chapter 18A. As of August 2026, 41 of them trade below their IPO price, and 12 have seen their valuations fall by more than 70 per cent.

The problem is not market sentiment. The problem is that listing has become a financing milestone rather than a validation of commercial readiness. Companies that go public with one product candidate in Phase II trials and no revenue model face brutal scrutiny from institutional investors who expected a different risk profile. The disconnect between venture expectations and public market discipline has left many healthcare companies stranded in a no-man's-land, too expensive for venture follow-on and too risky for crossover funds.

Dr Tsang argued that strategic investors, particularly hospital operators and pharmaceutical distributors, can bridge this gap. IHH Healthcare North Asia has taken minority stakes in several digital health platforms, not as financial bets but as operational partnerships. These investments come with guaranteed pilot programmes, access to patient data (under strict privacy protocols), and co-development agreements that de-risk the product roadmap. This model does not generate venture-style returns, but it generates sustainable businesses.

Reimbursement as the Real Gatekeeper

China's National Healthcare Security Administration, established in 2018, centralized drug pricing negotiations and expanded the national reimbursement catalogue. For pharmaceuticals, this created a clearer pathway. For medical devices and digital health tools, the picture remains fragmented. Provincial and municipal health authorities retain significant discretion over reimbursement for non-pharmaceutical interventions, and the criteria vary widely.

A telemedicine platform that secures reimbursement in Zhejiang may find itself excluded in Guangdong. An AI diagnostic tool approved for reimbursement in Beijing's public hospitals may not qualify in Shenzhen's private facilities. This patchwork forces healthcare startups to pursue a province-by-province strategy that demands local expertise, political capital, and patience. Venture funds, accustomed to scaling software businesses across borders in 18 months, often underestimate the friction.

Leung pointed out that successful healthcare investors in China now operate more like private equity firms than traditional venture capitalists. They hold board seats, negotiate reimbursement deals alongside management teams, and use their networks to accelerate hospital adoptions. This is not passive capital. It is strategic capital, and it requires a different skill set.

What Comes Next

The healthcare investment landscape in Greater China is maturing, but it is not becoming easier. The next wave of successful companies will likely emerge from those that understand reimbursement strategy before they finalize product design, that build hospital partnerships during clinical trials rather than after launch, and that treat regulatory approval as the starting line rather than the finish line.

For investors, this means longer hold periods, deeper operational involvement, and a willingness to co-invest with strategic partners who bring distribution capabilities. The days of funding a brilliant team with a promising molecule and expecting a liquid exit in five years are over. The capital lifecycle in healthcare is no longer linear. It is iterative, and it demands patience that most venture models were not built to accommodate.

The Shanghai roundtable did not produce easy answers, but it clarified the question: how do you build healthcare businesses in a market where clinical innovation outpaces commercial infrastructure? The investors and operators who solve that problem will define the next decade of the sector. Those who ignore it will continue to fund companies that never escape the valley.